Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies [0.03%]
开发用于B细胞恶性肿瘤的三特异性CAR-T面临的挑战和考虑因素
Uday Kulkarni,Marcos de Lima,Boro Dropulic et al.
Uday Kulkarni et al.
Improving care for children with juvenile idiopathic arthritis: the role of IL-6 inhibitors in a patient-centered approach [0.03%]
改善对幼年特发性关节炎患儿护理：以患者为中心的方法中IL-6抑制剂的作用
Gabriele Simonini,Jordi Antón,Gerd Horneff et al.
Gabriele Simonini et al.
Introduction: Medical management of juvenile idiopathic arthritis (JIA) presents a significant challenge in pediatric rheumatology. Ideally, the treatment target is remission, though achieving this remains complex. Interl...
Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial [0.03%]
生物仿制药Bmab 1200与原研乌司奴单抗治疗中重度斑块状银屑病疗效和安全性的对比：III期STELLAR-2研究52周结果
Jacek C Szepietowski,Adam Reich,Steven R Feldman et al.
Jacek C Szepietowski et al.
Background: The STELLAR-2 study compared the efficacy, safety, immunogenicity, and pharmacokinetics of Bmab 1200 with reference ustekinumab through Week 52 in patients with moderate-to-severe chronic plaque psoriasis. ...
Albert Oriol,Gladys Ibarra,Jordi Loscos et al.
Albert Oriol et al.
Introduction: Advances in frontline multiple myeloma (MM) treatment, through combinatorial regimens with diverse mechanisms of action, have created a need for alternative agents at relapse. BCMA-targeting CAR-T therapies ...
Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients [0.03%]
832例地中海发热家系患者的生物治疗评估：回顾性研究
Yasam Doruk Pervane,Esra Bağlan
Yasam Doruk Pervane
Objective: Biologic agents have been used in colchicine-resistant familial Mediterranean fever (FMF) patients and in patients with comorbidities including juvenile idiopathic arthritis (JIA). The main aim of our study was...
Improving health literacy and patient-directed knowledge of fecal microbiota transplantation (FMT) through analysis of readability: a cross sectional infodemiology study [0.03%]
通过可读性分析改善粪便微生物移植的健康素养和患者导向知识：横断面信息流行病学研究
John E Moore,Beverley C Millar
John E Moore
Background: Fecal microbiota transplantation (FMT) is increasingly used in geriatric medicine, including intestinal decolonization of antimicrobial-resistant bacterial pathogens and the treatment of inflammatory bowel dis...
Progress in the use of biological therapies to treat paroxysmal nocturnal hemoglobinuria: focus on patient profiling [0.03%]
评估生物疗法治疗阵发性睡眠性血红蛋白尿症的进展：重点关注患者分层和预后标志物
Francesco Versino,Bruno Fattizzo
Francesco Versino
Introduction: Complement inhibition has revolutionized paroxysmal nocturnal hemoglobinuria (PNH) treatment. While eculizumab, the first anti-C5 antibody, reduced intravascular hemolysis (IVH) and thrombotic risk, it requi...
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety and immunogenicity of BAT1806 SC with Tocilizumab in healthy Chinese male subjects [0.03%]
托珠单抗BAT1806与雅美罗在健康受试者中的随机、双盲、单次给药、平行对照的生物等效性及免疫原性Ⅰ期临床试验
Qin Yang,Yan Jiang,Zhijie Liu et al.
Qin Yang et al.
Background: This study compared the pharmacokinetics (PK), safety, and immunogenicity of the tocilizumab biosimilar, BAT1806 SC (Tocilizumab biosimilar, Subcutaneous Injection), with Tocilizumab (RoActemra®) in healthy C...
Clinical and out-of-pocket cost outcomes after switching to biosimilar adalimumab-atto in patients with rheumatoid arthritis [0.03%]
风湿性关节炎患者换用生物仿制药adalimumab-atto后的临床和自付费用结果
Antony T-H Lin,Fang Niu,Rita L Hui et al.
Antony T-H Lin et al.
Background: Limited real-world studies have evaluated outcomes after switching treatment from a reference product (RP) to a biosimilar product. The objective of this real-world study was to assess the outcomes of switchin...
An evaluation of nipocalimab for the treatment of generalized myasthenia gravis [0.03%]
尼波卡利姆治疗全身性重症肌无力的评估研究
Carlo Antozzi,Marie Fitzgibbon
Carlo Antozzi
Introduction: Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies targeting the neuromuscular junction. MG, characterized clinically by fluctuating muscle weakness and fatigability, is traditionally t...